Hadile Ounallah Saad

Company: Clexio Biosciences

Job title: Head of Innovation early stage pipeline

Seminars:

Introducing CLE-905, a Potent Dual M1/M4 Receptor Agonist in Development for Schizophrenia and BPSD 3:50 pm

Mechanism of Action – discussing the potential contribution of M1 and M4 receptor agonism CLE-905 demonstrated dose dependent robust antipsychotic effect in pharmacological models, IND enabling studies ongoingRead more

day: Conference Day 1 PM